Public Employees Retirement System of Ohio Lowers Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Public Employees Retirement System of Ohio cut its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 8.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 104,633 shares of the biotechnology company's stock after selling 9,119 shares during the quarter. Public Employees Retirement System of Ohio's holdings in Exelixis were worth $3,484,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Coppell Advisory Solutions LLC acquired a new position in shares of Exelixis in the 4th quarter valued at about $25,000. Colonial Trust Co SC lifted its stake in shares of Exelixis by 616.9% in the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 765 shares during the period. Principal Securities Inc. lifted its stake in shares of Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 373 shares during the period. Kestra Investment Management LLC acquired a new position in shares of Exelixis in the 4th quarter valued at about $39,000. Finally, Crowley Wealth Management Inc. acquired a new position in Exelixis during the 4th quarter worth approximately $50,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Trading Down 1.1%

Shares of NASDAQ:EXEL traded down $0.45 on Wednesday, reaching $42.22. 1,787,390 shares of the company traded hands, compared to its average volume of 2,328,020. The business's 50-day simple moving average is $38.79 and its 200 day simple moving average is $36.53. Exelixis, Inc. has a 52 week low of $21.36 and a 52 week high of $48.85. The stock has a market capitalization of $11.51 billion, a P/E ratio of 23.85, a price-to-earnings-growth ratio of 1.13 and a beta of 0.28.

Analysts Set New Price Targets

EXEL has been the topic of a number of research reports. UBS Group reaffirmed an "underperform" rating on shares of Exelixis in a research note on Thursday, April 17th. Stifel Nicolaus upped their price target on Exelixis from $36.00 to $38.00 and gave the stock a "hold" rating in a research note on Wednesday, May 14th. Barclays upped their price target on Exelixis from $25.00 to $29.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 13th. JMP Securities reissued a "market outperform" rating and set a $41.00 price objective on shares of Exelixis in a report on Thursday, April 17th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of Exelixis in a report on Thursday, March 27th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $38.94.

Insider Buying and Selling

In other Exelixis news, CMO Amy C. Peterson sold 72,776 shares of Exelixis stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $45.47, for a total transaction of $3,309,124.72. Following the sale, the chief marketing officer now directly owns 465,393 shares of the company's stock, valued at approximately $21,161,419.71. The trade was a 13.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jack L. Wyszomierski sold 7,535 shares of Exelixis stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $43.09, for a total value of $324,683.15. Following the sale, the director now directly owns 358,882 shares in the company, valued at approximately $15,464,225.38. The trade was a 2.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 458,113 shares of company stock valued at $21,024,817 over the last ninety days. 2.85% of the stock is owned by insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.